Published in Blood on September 11, 2003
Is telomerase a viable target in cancer? Mutat Res (2011) 1.23
Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS One (2010) 1.19
Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget (2013) 1.10
Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer (2005) 0.97
Telomerase inhibition in cancer therapeutics: molecular-based approaches. Curr Med Chem (2006) 0.87
A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112). Clin Cancer Res (2013) 0.86
Antisense oligonucleotides and all-trans retinoic acid have a synergistic anti-tumor effect on oral squamous cell carcinoma. BMC Cancer (2008) 0.83
Therapeutic targeting of replicative immortality. Semin Cancer Biol (2015) 0.83
Therapeutic inhibition of TRF1 impairs the growth of p53-deficient K-RasG12V-induced lung cancer by induction of telomeric DNA damage. EMBO Mol Med (2015) 0.81
Targeting human telomerase for cancer therapeutics. Cytotechnology (2004) 0.79
Inhibitory effect of human telomerase antisense oligodeoxyribonucleotides on the growth of gastric cancer cell lines in variant tumor pathological subtype. World J Gastroenterol (2005) 0.79
The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma. Cancer Biol Ther (2015) 0.78
Telomere-driven diseases and telomere-targeting therapies. J Cell Biol (2017) 0.77
Creation of a novel telomere-cutting endonuclease based on the EN domain of telomere-specific non-long terminal repeat retrotransposon, TRAS1. Mob DNA (2010) 0.76
New prospects for targeting telomerase beyond the telomere. Nat Rev Cancer (2016) 0.76
Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner. Oncotarget (2016) 0.75
Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell (2002) 9.36
Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med (2002) 4.00
AID is required for c-myc/IgH chromosome translocations in vivo. Cell (2004) 3.89
Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nat Biotechnol (2003) 3.43
Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. Cell (2006) 3.31
Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol (2009) 2.70
RNA export factor RAE1 contributes to NUP98-HOXA9-mediated leukemogenesis. Cell Cycle (2011) 2.18
Generation of functional hemangioblasts from human embryonic stem cells. Nat Methods (2007) 2.06
A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res (2006) 1.99
The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood (2005) 1.84
The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood (2002) 1.84
The migrastatin family: discovery of potent cell migration inhibitors by chemical synthesis. J Am Chem Soc (2004) 1.67
Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene (2005) 1.64
Tunneling nanotubes provide a unique conduit for intercellular transfer of cellular contents in human malignant pleural mesothelioma. PLoS One (2012) 1.63
In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res (2005) 1.59
Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. Blood (2003) 1.59
Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood (2004) 1.46
Constitutive activation of STAT5A promotes human hematopoietic stem cell self-renewal and erythroid differentiation. J Exp Med (2004) 1.44
Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia. Cancer Cell (2012) 1.40
Nrf2 regulates haematopoietic stem cell function. Nat Cell Biol (2013) 1.38
NF-kappa B1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-kappa B2 p100 to p52 in quiescent mature B cells. J Immunol (2003) 1.38
A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer Res (2008) 1.38
Angiogenic factors reconstitute hematopoiesis by recruiting stem cells from bone marrow microenvironment. Ann N Y Acad Sci (2003) 1.36
Telomerase-based pharmacologic enhancement of antiviral function of human CD8+ T lymphocytes. J Immunol (2008) 1.34
Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer Res (2005) 1.33
Early hematopoietic zinc finger protein (EHZF), the human homolog to mouse Evi3, is highly expressed in primitive human hematopoietic cells. Blood (2003) 1.27
Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma (2003) 1.25
Enforced expression of NUP98-HOXA9 in human CD34(+) cells enhances stem cell proliferation. Cancer Res (2006) 1.25
Critical role for Kit-mediated Src kinase but not PI 3-kinase signaling in pro T and pro B cell development. J Exp Med (2004) 1.22
Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1. Proc Natl Acad Sci U S A (2004) 1.21
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol (2007) 1.21
Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res (2008) 1.19
Diverted total synthesis leads to the generation of promising cell-migration inhibitors for treatment of tumor metastasis: in vivo and mechanistic studies on the migrastatin core ether analog. J Am Chem Soc (2010) 1.19
CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells. Immunity (2002) 1.18
Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother (2006) 1.15
A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res (2003) 1.15
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. Br J Haematol (2008) 1.14
MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin. Clin Cancer Res (2011) 1.14
Telomere length assessment in tissue sections by quantitative FISH: image analysis algorithms. Cytometry A (2004) 1.14
Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N-ras. Oncogene (2002) 1.12
Oligonucleotide N3'-->P5' phosphoramidates as efficient telomerase inhibitors. Oncogene (2002) 1.11
Increased plasma levels of stromal-derived factor-1 (SDF-1/CXCL12) enhance human thrombopoiesis and mobilize human colony-forming cells (CFC) in NOD/SCID mice. Exp Hematol (2004) 1.11
Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. Blood (2012) 1.11
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol (2010) 1.10
Tunneling Nanotubes: A new paradigm for studying intercellular communication and therapeutics in cancer. Commun Integr Biol (2012) 1.08
Enforced activation of STAT5A facilitates the generation of embryonic stem-derived hematopoietic stem cells that contribute to hematopoiesis in vivo. Stem Cells (2004) 1.08
Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival. Blood (2003) 1.08
Elevated telomerase activity and minimal telomere loss in cord blood long-term cultures with extensive stem cell replication. Blood (2004) 1.06
Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res Treat (2005) 1.05
Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo. Clin Cancer Res (2008) 1.04
Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells. Oncogene (2004) 1.04
Interaction of human telomerase with its primer substrate. Biochemistry (2003) 1.04
Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology (2005) 1.04
Early hematopoietic zinc finger protein-zinc finger protein 521: a candidate regulator of diverse immature cells. Int J Biochem Cell Biol (2007) 1.04
Limited proliferation and telomere dysfunction following telomerase inhibition in immortal murine fibroblasts. Cancer Res (2002) 1.03
Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res (2003) 1.03
Enforced expression of an Flt3 internal tandem duplication in human CD34+ cells confers properties of self-renewal and enhanced erythropoiesis. Blood (2004) 1.02
Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts. Neuro Oncol (2004) 0.98
Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1. Cell Cycle (2013) 0.98
Emergence of potent inhibitors of metastasis in lung cancer via syntheses based on migrastatin. Proc Natl Acad Sci U S A (2011) 0.97
Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. Cancer Immun (2010) 0.97
Zinc finger protein 521 antagonizes early B-cell factor 1 and modulates the B-lymphoid differentiation of primary hematopoietic progenitors. Cell Cycle (2011) 0.97
At last: erythropoietin as a single glycoform. Angew Chem Int Ed Engl (2012) 0.97
Generation of a human airway epithelium derived basal cell line with multipotent differentiation capacity. Respir Res (2013) 0.96
Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer (2010) 0.96
Telomere shortening sensitizes cancer cells to selected cytotoxic agents: in vitro and in vivo studies and putative mechanisms. PLoS One (2010) 0.95
The effect of cantharidins on leukemic stem cells. Int J Cancer (2009) 0.94
Regeneration of the infarcted heart with stem cells derived by nuclear transplantation. Circ Res (2004) 0.94
Luteinizing hormone-releasing hormone enhances T cell recovery following allogeneic bone marrow transplantation. J Immunol (2009) 0.93
Mechanism of BLyS action in B cell immunity. Cytokine Growth Factor Rev (2002) 0.93
Stromal cell lines from the aorta-gonado-mesonephros region are potent supporters of murine and human hematopoiesis. Exp Hematol (2006) 0.92
Loop-loop interaction of HIV-1 TAR RNA with N3'-->P5' deoxyphosphoramidate aptamers inhibits in vitro Tat-mediated transcription. Proc Natl Acad Sci U S A (2002) 0.91
STAT5-induced self-renewal and impaired myelopoiesis of human hematopoietic stem/progenitor cells involves down-modulation of C/EBPalpha. Blood (2006) 0.91
Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment. PLoS One (2009) 0.90
Airway basal cells of healthy smokers express an embryonic stem cell signature relevant to lung cancer. Stem Cells (2013) 0.90
Noxa mediates p18INK4c cell-cycle control of homeostasis in B cells and plasma cell precursors. Blood (2010) 0.90
Benign mesenchymal stromal cells in human sarcomas. Clin Cancer Res (2010) 0.90
TRAIL/Apo-2 ligand induces primary plasma cell apoptosis. J Immunol (2002) 0.89
Improved ex vivo expansion of adult hematopoietic stem cells by overcoming CUL4-mediated degradation of HOXB4. Blood (2013) 0.88
Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci U S A (2012) 0.87
Smoking accelerates aging of the small airway epithelium. Respir Res (2014) 0.87
Osteopetrotic mouse stroma with thrombopoietin, c-kit ligand, and flk-2 ligand supports long-term mobilized CD34+ hematopoiesis in vitro. Stem Cells Dev (2005) 0.87
Kit ligand cytoplasmic domain is essential for basolateral sorting in vivo and has roles in spermatogenesis and hematopoiesis. Dev Biol (2009) 0.86
Total synthesis of peribysin E necessitates revision of the assignment of its absolute configuration. Angew Chem Int Ed Engl (2007) 0.86
Novel RNA regulatory mechanisms revealed in the epitranscriptome. RNA Biol (2013) 0.86
Anticancer activity of a broccoli derivative, sulforaphane, in barrett adenocarcinoma: potential use in chemoprevention and as adjuvant in chemotherapy. Transl Oncol (2010) 0.86
Allosteric inhibitors of telomerase: oligonucleotide N3'-->P5' phosphoramidates. Nucleic Acids Res (2002) 0.85
Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins. J Leukoc Biol (2004) 0.84